Provided by Tiger Trade Technology Pte. Ltd.

Acumen Pharmaceuticals, Inc.

2.92
0.0000
Post-market: 2.960.0400+1.37%19:01 EDT
Volume:577.13K
Turnover:1.69M
Market Cap:176.87M
PE:-1.32
High:3.04
Open:2.87
Low:2.80
Close:2.92
52wk High:3.60
52wk Low:0.8551
Shares:60.57M
Float Shares:32.93M
Volume Ratio:0.26
T/O Rate:1.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2064
EPS(LYR):-1.7051
ROE:-85.93%
ROA:-42.23%
PB:1.90
PE(LYR):-1.71

Loading ...

Acumen Pharmaceuticals Inc. to report fourth-quarter and full-year financial results and host conference call

Reuters
·
3 hours ago

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026

GlobeNewswire
·
3 hours ago

Acumen announces new research findings at Alzheimer’s and Parkinson’s conference

TIPRANKS
·
Mar 17

Acumen presents Phase 1 INTERCEPT-AD biomarker results for sabirnetug at AD/PD 2026

Reuters
·
Mar 17

Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026

GlobeNewswire
·
Mar 17

Maintaining Buy on Acumen (ABOS): EBD-Enabled Alzheimer’s Pipeline, Extended Runway, and Discounted Valuation Ahead of ALTITUDE-AD Readout

TIPRANKS
·
Mar 17

Acumen Pharmaceuticals Is Maintained at Buy by BTIG

Dow Jones
·
Mar 17

Acumen price target raised to $8 from $7 at BTIG

TIPRANKS
·
Mar 17

BUZZ-U.S. STOCKS ON THE MOVE-Customers Bancorp, Forgent Power Solutions, Nvidia

Reuters
·
Mar 17

BUZZ-U.S. STOCKS ON THE MOVE-Dollar Tree, Micron, Customers Bancorp

Reuters
·
Mar 16

Acumen Raises Capital to Advance Enhanced Brain Delivery

TIPRANKS
·
Mar 16

Acumen Pharmaceuticals Shares Up on Positive Alzheimer's Drug Data, $35.8M Private Placement

Dow Jones
·
Mar 16

Acumen Pharmaceuticals publishes corporate presentation on sabirnetug (ACU193) Phase 2 program for early Alzheimer’s disease

Reuters
·
Mar 16

Acumen Pharmaceuticals announces USD 35.75 million private placement at USD 3.3 per share

Reuters
·
Mar 16

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

GlobeNewswire
·
Mar 16

Acumen Pharmaceuticals to join Stifel 2026 Virtual CNS Forum fireside chat

Reuters
·
Mar 11

Acumen Pharmaceuticals Chief Legal Officer Derek Meisner Disposes of Common Shares

Reuters
·
Mar 04

Acumen Pharmaceuticals to Present Alzheimer’s Treatment Advances at AD/PD 2026 Conference

Reuters
·
Mar 03

Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026

THOMSON REUTERS
·
Mar 03

Analysts Are Bullish on These Healthcare Stocks: vTv Therapeutics (VTVT), Acumen Pharmaceuticals (ABOS)

TIPRANKS
·
Feb 03